Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2020 Earnings Conference Call November 10, 2020 4:30 PM ET Company Participants Karina Calzadilla – Investor Relations Chad Robins – Chief Executive Officer and Co-Founder Julie Rubinstein – President Chad Cohen – Chief Financial Officer Harlan Robins – Chief Scientific Officer and Co-Founder Conference Call Participants Tycho Peterson – J.P. Morgan Derik de Bruin – Bank of America Doug Schenkel – Cowen Salveen Richter – Goldman Sachs Brian Weinstein – W ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES COR ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2020 Results Earnings Conference Call August 11, 2020 4:30 PM ET Company Participants Karina Calzadilla - Vice President, Investor Relations Chad Robins - Co-founder and Chief Executive Officer Julie Rubinstein - President Chad Cohen - Chief Financial Officer Harlan Robins – Chief Scientific Officer and Co-Founder Conference Call Participants Derik de Bruin - Bank of America Merrill Lynch Tycho Peterson - J.P. Morgan Doug Schenkel - Cowen and Company Sal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORAT ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2020 Results Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Chad Robins - Co-founder and Chief Executive Officer Julie Rubinstein - President Chad Cohen - Chief Financial Officer Harlan Robins – Chief Scientific Officer and Co-Founder Conference Call Participants Brian Weinstein - William Blair Doug Schenkel - Cowen Tycho Peterson - JPMorgan Derik De Bruin - Bank of America David Westenberg - Gu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-090702 ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2019 Earnings Conference Call February 26, 2020 4:30 PM ET Company Participants Carrie Mendivil – Investor Relations Chad Robins – Co-founder and Chief Executive Officer Julie Rubinstein – President Chad Cohen – Chief Financial Officer Harlan Robins – Chief Scientific Officer and Co-Founder Conference Call Participants Brian Weinstein – William Blair Subbu Nambi – Cowen Ivy Ma - Bank of America Max Smock – BTIG David Westenberg – Guggenheim Securities Op ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (St ...